arrow
H

Hayato Koba

Kanazawa University
H指数:11
被引数:776

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers

克服HER2-Positive癌症中曲妥珠单抗Deruxtecan有效载荷耐药性的治疗策略

2026-01-170
OAAI
Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer

EGFR突变非小细胞肺癌中术前ctDNA和病理静脉侵犯对复发的预测价值

2025-11-040
PRE
A 72-Year-Old Man With Progressive Dyspnea and Diffuse Lung Disease

一位72岁男性,主诉进行性呼吸困难及弥漫性肺部疾病

CHEST
IF8.6
2025-07-080
PRE
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

帕博利珠单抗作为非小细胞肺癌患者(PD-L1肿瘤比例评分≥50%)一线治疗的五年疗效和安全性:一项多中心观察性研究

2025-03-011
PRE
EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer
2024-11-010
OAAI
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings

在现实环境中使用免疫检查点抑制剂单药治疗的非小细胞肺癌患者的长期生存

2022-09-0115
PRE
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

新型冠状病毒肺炎住院患者早期与晚期Favipiravir治疗的前瞻性,随机,开放标签试验

2020-11-17176
OAAI